Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has appointed entrepreneur and corporate finance executive Lourdes Felix to its board of directors.
The Freehold, New Jersey-based biotechnology company noted that Felix has 30 years of combined experience in capital markets, public accounting and in the private sector. She presently serves as CEO, chief financial officer, and director of BioCorRx Inc, a leader in addiction treatment solutions and related disorders, where she has been since October 2012.
“She brings a wealth of expertise in both therapeutic development and addiction programs, which we believe will be valuable as we look to implement a roll-up strategy targeting toxicology labs, including within the addiction sector,” Avalon president and CEO Dr David Jin said in a statement. “We believe her deep understanding of the industry, along with her contacts in the private and government sectors will be instrumental in growing our business.”
READ: Avalon GloboCare reveals deployment of breakthrough fusion gene map technology
The company said Felix, one of the founders and president of BioCorRx subsidiary BioCorRx Pharmaceuticals Inc, has been instrumental in capital procurement, completing multi-million dollar equity financings, and is accomplished in structuring and negotiating transactions.
Along with other executives of the company, she restructured and expanded the business model to position it for long-term growth in the addiction treatment space and drug development. She also has extensive experience with clinic operations management, it added.
“We believe her strong background in finance, regulatory matters and the public markets also reinforces our commitment to the highest levels of corporate governance,” Jin added.
Prior to joining BioCorRx, Felix’s experience was in the private sector and public accounting. She has a thorough knowledge of federal and state regulations and has successfully managed and produced SEC regulatory filings.
She holds a Bachelor of Science degree in Accounting from the University of Phoenix and is an MBA candidate at D’Amore-McKim School of Business, Northeastern University.
“I’m thrilled to be joining Avalon at such an exciting time,” Felix said. “I look forward to working closely with management and helping drive the growth of the company by taking advantage of a unique roll-up opportunity within the highly fragmented market of toxicology labs.”
Avalon develops innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.
Contact the author at stephen.gunnion@proactiveinvestors.com